Protein Summary
Involved in pre-mRNA splicing. Functions in association with cyclin-dependent kinases (CDKs) (PubMed:18216018). Inhibited by the CDK-specific inhibitor CDKN1A/p21 (PubMed:11980906). May play a role in the regulation of RNA polymerase II (pol II). May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC) (PubMed:12414649, PubMed:15700036).
- ENST00000295925
- ENSP00000295925
- ENSG00000163660
- ENST00000295926
- ENSP00000295926
- ENST00000461804
- ENSP00000420277
- ENST00000465947
- ENSP00000418094
- ENST00000470121
- ENSP00000417237
- ENST00000475298
- ENSP00000417343
- ENST00000477127
- ENSP00000418449
- ENST00000631619
- ENSP00000487951
- ANIA6A
- BM-001
- PRO1073
- ania-6a
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor binding site profile | 0.99 | ||
virus perturbation | 0.99 | ||
drug perturbation | 0.96 | ||
transcription factor perturbation | 0.8 | ||
cell type or tissue | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 18.9 (req: < 5)
Gene RIFs: 17 (req: <= 3)
Antibodies: 205 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 18.9 (req: >= 5)
Gene RIFs: 17 (req: > 3)
Antibodies: 205 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0